| Title |
Elevated level of peripheral CD8+CD28− T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, April 2013
|
| DOI | 10.1007/s00262-013-1424-8 |
| Pubmed ID | |
| Authors |
Guohong Song, Xiaoli Wang, Jun Jia, Yanhua Yuan, Fengling Wan, Xinna Zhou, Huabing Yang, Jun Ren, Jiezhun Gu, Herbert Kim Lyerly |
| Abstract |
Suppression of cellular immunity resulting from tumorigenesis and/or therapy might promote cancer cells' growth, progression and invasion. Here, we explored whether T lymphocyte subtypes from peripheral blood of metastatic breast cancer (MBC) female patients could be used as alternative surrogate markers for cancer progress. Additionally, plasma levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IFN-γ, and transforming growth factor-β1 were quantitated from MBC and healthy volunteers. |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 32% |
| Researcher | 5 | 15% |
| Student > Master | 4 | 12% |
| Other | 3 | 9% |
| Student > Bachelor | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 4 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 35% |
| Immunology and Microbiology | 8 | 24% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Agricultural and Biological Sciences | 2 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 6 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2013.
All research outputs
#15,274,524
of 22,714,025 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,155
of 2,889 outputs
Outputs of similar age
#123,197
of 197,147 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#22
of 23 outputs
Altmetric has tracked 22,714,025 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,889 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,147 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.